Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors

被引:89
|
作者
Young, MB
Barrow, JC
Glass, KL
Lundell, GF
Newton, CL
Pellicore, JM
Rittle, KE
Selnick, HG
Stauffer, KJ
Vacca, JP
Williams, PD
Bohn, D
Clayton, FC
Cook, JJ
Krueger, JA
Kuo, LC
Lewis, SD
Lucas, BJ
McMasters, DR
Miller-Stein, C
Pietrak, BL
Wallace, AA
White, RB
Wong, B
Yan, YW
Nantermet, PG
机构
[1] Merck & Co Inc, Merck Res Labs, Med Chem, West Point, PA 19486 USA
[2] Merck & Co Inc, Merck Res Labs, Pharmacol, West Point, PA 19486 USA
[3] Merck & Co Inc, Merck Res Labs, Biol Chem, West Point, PA 19486 USA
[4] Merck & Co Inc, Merck Res Labs, Struct Biol, West Point, PA 19486 USA
[5] Merck & Co Inc, Merck Res Labs, Mol Syst, West Point, PA 19486 USA
[6] Merck & Co Inc, Merck Res Labs, Drug Metab, West Point, PA 19486 USA
关键词
D O I
10.1021/jm030303e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In an effort to discover potent, clinically useful thrombin inhibitors, a rapid analogue synthetic approach was used to explore the P-1 region. Various benzylamines were coupled to a pyridine/pyrazinone P-2-P-3 template. One compound with an o-thiadiazole benzylic substitution was found to have a thrombin K-i of 0.84 nM. A study of ortho-substituted five-membered-ring heterocycles was undertaken and subsequently demonstrated that the o-triazole and tetrazole rings were optimal. Combination of these potent P-1 aryl heterocycles with a variety of P-2-P-3 groups produced a compound with an extraordinary thrombin inhibitory activity of 1.4 pM. It is hoped that this potency enhancement in P-1 will allow for more diversification in the P-2-P-3 region to ultimately address additional pharmacological concerns.
引用
收藏
页码:2995 / 3008
页数:14
相关论文
共 50 条
  • [1] Quantitative structure activity relationship studies of aryl heterocycle-based thrombin inhibitors
    Deswal, Sumit
    Roy, Nilanjan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2006, 41 (11) : 1339 - 1346
  • [2] Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists
    Kiyoi, Takao
    Adam, Julia M.
    Clark, John K.
    Davies, Keneth
    Easson, Anna-Marie
    Edwards, Darren
    Feilden, Helen
    Fields, Ruth
    Francis, Stuart
    Jeremiah, Fiona
    McArthur, Duncan
    Morrison, Angus J.
    Prosser, Alan
    Ratcliffe, Paul D.
    Schulz, Jurgen
    Wishart, Grant
    Baker, James
    Campbell, Robert
    Cottney, Jean E.
    Deehan, Maureen
    Epemolu, Ola
    Evans, Louise
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (06) : 1748 - 1753
  • [3] Heterocycle-based MMP inhibitors with P2′ substituents
    Pikul, S
    Dunham, KM
    Almstead, NG
    De, B
    Natchus, MG
    Taiwo, YO
    Williams, LE
    Hynd, BA
    Hsieh, LC
    Janusz, MJ
    Gu, F
    Mieling, GE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (08) : 1009 - 1013
  • [4] The discovery of orally available thrombin inhibitors: Optimisation of the P1 pharmacophore
    Ambler, J
    Bentley, D
    Brown, L
    Dunnet, K
    Farr, D
    Janus, D
    Le Grand, D
    Menear, K
    Mercer, M
    Talbot, M
    Tweed, M
    Wathey, B
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (08) : 1103 - 1108
  • [5] Potent and selective bicyclic lactam inhibitors of thrombin: Part 2: P1 modifications
    Plummer, JS
    Berryman, KA
    Cai, C
    Cody, WL
    DiMaio, J
    Doherty, AM
    Edmunds, JJ
    He, JX
    Holland, DR
    Levesque, S
    Kent, DR
    Narasimhan, LS
    Rubin, JR
    Rapundalo, ST
    Siddiqui, MA
    Susser, AJ
    St-Denis, Y
    Winocour, PD
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (23) : 3409 - 3414
  • [6] Potent and selective bicyclic lactam inhibitors of thrombin:: Part 3:: P1′ modifications
    Plummer, JS
    Berryman, KA
    Cai, CM
    Cody, WL
    DiMaio, J
    Doherty, AM
    Eaton, S
    Edmunds, JJ
    Holland, DR
    Lafleur, D
    Levesque, S
    Narasimhan, LS
    Rubin, JR
    Rapundalo, T
    Siddiqui, MA
    Susser, A
    St-Denis, Y
    Winocour, P
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (06) : 835 - 840
  • [7] Synthesis of new heterocycle-based selenoamides as potent cytotoxic agents
    Garcia-Lopez, J. G.
    Gutierrez-Hernandez, A., I
    Toscano, R. A.
    Ramirez-Apan, M. T.
    Terron, J. A.
    Ortega-Alfaro, M. C.
    Lopez-Cortes, J. G.
    ARKIVOC, 2021, : 13 - 24
  • [8] Noncovalent thrombin inhibitors incorporating an imidazolylethynyl P1
    Lee, K
    Jung, WH
    Kang, M
    Lee, SH
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (24) : 2775 - 2778
  • [9] Thrombin receptor (PAR-1) antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motif
    Hoekstra, WJ
    Hulshizer, BL
    McComsey, DF
    Andrade-Gordon, P
    Kauffman, JA
    Addo, MF
    Oksenberg, D
    Scarborough, RM
    Maryanoff, BE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (13) : 1649 - 1654
  • [10] Design and synthesis of novel heterocycle-based inhibitors of plasminogen activator inhibitor-1
    Guntaka, Naga S.
    Anumala, Himabindu
    Saraha, Hasina Y.
    Weerakoon, Darshani A.
    Burke, Sarah J.
    Van Strien, Daniel K.
    Saad, Ebaa S.
    Warnock, Mark
    Lawrence, Daniel A.
    Emal, Cory D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245